US Patent

US11186547 — High-purity quinoline derivative and method for manufacturing same

Composition of Matter · Assigned to Eisai R&D Management Co Ltd · Expires 2035-08-26 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a high-purity quinoline derivative represented by formula (IV) or a salt thereof with a content of compound represented by formula (I) of 350 ppm by mass or less.

USPTO Abstract

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

Drugs covered by this patent

Patent Metadata

Patent number
US11186547
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-08-26
Drug substance claim
Yes
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.